K. Hatano

Publications66
h-index11
Citations487
Highly Influential Citations15
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • Y. Kanda
  • 778 Publications • 20,165 Citations
  • K. Muroi
  • 285 Publications • 3,326 Citations
  • S. Fujiwara
  • 151 Publications • 5,547 Citations
  • R. Yamasaki
  • 83 Publications • 636 Citations
  • Publications
  • Influence
Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma
TLDR
Functional screening using short hairpin RNA suggests that VLA-4 plays a critical role in CAM-DR of MM cells, and the combination of bortezomib with conventional anti-myeloma drugs may be effective in overcoming CAM- DR of MM.
View on Nature
Therapy-related acute myeloid leukemia and myelodysplastic syndrome after hematopoietic cell transplantation for lymphoma
Therapy-related acute myeloid leukemia and myelodysplastic syndrome (t-AML/MDS) represent severe late effects in patients receiving hematopoietic cell transplantation (HCT) for lymphoma. The choice…
View on Nature
A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid…
View on PubMed
Rituximab plus 70% cyclophosphamide, doxorubicin, vincristine and prednisone for Japanese patients with diffuse large B-cell lymphoma aged 70 years and older
TLDR
Three-year PFS with R-70%CHOP for patients aged 70 years and older was not significantly worse than that with full-dose R-CHop for younger patients, suggesting that R- 70% CHOP might be a reasonable choice for patients with DLBCL aged 70 year and older, especially for those with comorbidities.
View on Taylor & Francis
Comparison of gabexate mesilate and nafamostat mesilate for disseminated intravascular coagulation associated with hematological malignancies
TLDR
Resolution of DIC was correlated with improvement of background hematological malignancies, and no significant differences were observed between the two SPIs.
View on Springer
CD25 as an adverse prognostic factor in elderly patients with acute myeloid leukemia
TLDR
CD25 expression was increased at relapse and in the development of leukemic status from myelodysplastic syndrome or myeloproliferative neoplasm, and CD25 positivity was significantly correlated with an inferior complete remission (CR), event-free survival (EFS), and overall survival.
View on Taylor & Francis
Clinical outcomes of myeloid/lymphoid neoplasms with fibroblast growth factor receptor-1 (FGFR1) rearrangement
TLDR
Myeloid/lymphoid neoplasms with fibroblast growth factor receptor-1 (FGFR1) rearrangement are hematopoietic stem cell disorders with a poor prognosis, but no established standard therapy.
View on Taylor & Francis
Development of acute myeloid leukemia in patients with untreated chronic lymphocytic leukemia
TLDR
It is demonstrated that the development of AML in patients with untreated CLL was associated with a poor response to chemotherapy and an extremely poor prognosis.
View on Springer
Leukemia Cells Directly Phagocytose Blood Cells in AML-Associated Hemophagocytic Lymphohistiocytosis: A Case Report and Review of the Literature
TLDR
A 64-year-old man admitted to the authors' hospital with a 3-day history of high fever and oral bleeding was diagnosed as AML (M5b) with no chromosomal abnormality, in which leukemia cells primarily phagocytosed blood cells were identified.
View on PubMed
Clinical association between thyroid disease and immune thrombocytopenia
TLDR
It was demonstrated that thyroid diseases were commonly found in patients with ITP, and treatment of the underlying thyroid disease may improve thrombocytopenia.
View on Springer
...
...